L-天冬酰胺酶与6-重氮-5-氧代-L-正亮氨酸协同抑制胶质母细胞瘤细胞生长
本研究以U251、U87和SF767胶质母细胞瘤细胞为对象,评估靶向天冬酰胺代谢的治疗潜力。L-天冬酰胺酶和DON均以剂量依赖方式抑制细胞增殖,联合用药具有协同抗增殖效应,并可被外源性天冬酰胺逆转。联合治疗诱导的凋亡和自噬均多于单药治疗,提示该组合可能成为胶质母细胞瘤的新治疗选择。
要点
- L-天冬酰胺酶和DON均以剂量依赖方式抑制U251、U87和SF767胶质母细胞瘤细胞增殖。
- 两药联合对这些细胞系具有协同抗增殖作用,外源性天冬酰胺可逆转该抑制效应。
- 联合治疗诱导的凋亡和自噬均多于单药治疗,联合处理组天冬酰胺合成酶mRNA表达增加。
核心结论
- 结果提示L-天冬酰胺酶与DON联合可能成为胶质母细胞瘤患者的新治疗选择。
研究设计与样本
- 体外研究:以U251、U87和SF767胶质母细胞瘤细胞为对象,给予L-天冬酰胺酶和/或6-重氮-5-氧代-L-正亮氨酸(DON)处理。
主要发现
- 处理72小时后MTS法检测显示,L-天冬酰胺酶以剂量依赖方式抑制U251、U87和SF767细胞增殖。
- DON同样以剂量依赖方式抑制这些细胞系的增殖。
- 两药联合对这些细胞系具有协同抗增殖效应。
- 外源性天冬酰胺可逆转L-天冬酰胺酶和DON对增殖的抑制作用。
- 联合处理组细胞中天冬酰胺合成酶mRNA表达增加;联合治疗诱导的凋亡和自噬均多于单药治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma is an aggressive central nervous system tumor with a 5-year survival rate of < 10%. The standard therapy for glioblastoma is maximal safe resection, followed by radiation therapy and chemotherapy with temozolomide. New approaches to treatment of glioblastoma, such as targeting metabolism, have been studied. The object of this study is to evaluate whether asparagine could be a new target for treatment of glioblastoma. METHODS: We investigated a potential treatment for glioblastoma that targets the amino acid metabolism. U251, U87, and SF767 glioblastoma cells were treated with L-asparaginase and/or 6-diazo-5-oxo-L-norleucine (DON). L-asparaginase hydrolyzes asparagine into aspartate and depletes asparagine. L-asparaginase has been used for the treatment of acute lymphoblastic leukemia. DON is a glutamine analog that inhibits several glutamine-utilizing enzymes, including asparagine synthetase. RESULTS: Cell viability was measured after 72 h of treatment. MTS assay showed that L-asparaginase suppressed the proliferation of U251, U87, and SF767 cells in a dose-dependent manner. DON also inhibited the proliferation of these cell lines in a dose-dependent manner. Combined treatment with these drugs had a synergistic antiproliferative effect in these cell lines. Exogenous asparagine rescued the effect of inhibition of proliferation by L-asparaginase and DON. The expression of asparagine synthetase mRNA was increased in cells treated with a combination of L-asparaginase and DON. This combined treatment also induced greater apoptosis and autophagy than did single-drug treatment. CONCLUSION: The results suggest that the combination of L-asparaginase and DON could be a new therapeutic option for patients with glioblastoma.
引用
- Ohba S, Hirose Y. L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells. J Neurooncol. 2020. PMID: 32020477. doi:10.1007/s11060-019-03351-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。